

Shu Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1475170/publications.pdf>

Version: 2024-02-01

41
papers

2,542
citations

331538

21
h-index

395590

33
g-index

41
all docs

41
docs citations

41
times ranked

4944
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel insights of dietary polyphenols and obesity. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 1-18.	1.9	705
2	Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 363-376.	1.9	361
3	Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. <i>Journal of Nutritional Biochemistry</i> , 2018, 58, 1-16.	1.9	196
4	Quercetin-nanostructured lipid carriers: Characteristics and anti-breast cancer activities in vitro. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 113, 15-24.	2.5	184
5	Green tea catechins inhibit pancreatic phospholipase A2 and intestinal absorption of lipids in ovariectomized rats. <i>Journal of Nutritional Biochemistry</i> , 2006, 17, 492-498.	1.9	103
6	Anticancer activities of (^)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. <i>Journal of Liposome Research</i> , 2013, 23, 187-196.	1.5	102
7	Detection and treatment of atherosclerosis using nanoparticles. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1412.	3.3	89
8	Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals. <i>Chinese Journal of Natural Medicines</i> , 2015, 13, 641-652.	0.7	84
9	Nanoencapsulation Enhances Epigallocatechin-3-gallate Stability and Its Antiatherogenic Bioactivities in Macrophages. <i>Journal of Agricultural and Food Chemistry</i> , 2013, 61, 9200-9209.	2.4	75
10	Reduction in dietary omega-6 polyunsaturated fatty acids: Eicosapentaenoic acid plus docosahexaenoic acid ratio minimizes atherosclerotic lesion formation and inflammatory response in the LDL receptor null mouse. <i>Atherosclerosis</i> , 2009, 204, 147-155.	0.4	69
11	Resveratrol liposomes and lipid nanocarriers: Comparison of characteristics and inducing browning of white adipocytes. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 164, 414-423.	2.5	66
12	Autophagy in metabolic syndrome: breaking the wheel by targeting the renin-angiotensin system. <i>Cell Death and Disease</i> , 2020, 11, 87.	2.7	57
13	Epigallocatechin Gallate and Caffeine Differentially Inhibit the Intestinal Absorption of Cholesterol and Fat in Ovariectomized Rats. <i>Journal of Nutrition</i> , 2006, 136, 2791-2796.	1.3	50
14	In vitro fatty acid enrichment of macrophages alters inflammatory response and net cholesterol accumulation. <i>British Journal of Nutrition</i> , 2009, 102, 497.	1.2	49
15	Formulation, characteristics and antiatherogenic bioactivities of CD36-targeted epigallocatechin gallate (EGCG)-loaded nanoparticles. <i>Journal of Nutritional Biochemistry</i> , 2016, 30, 14-23.	1.9	45
16	Potential roles of vitamin E in age-related changes in skeletal muscle health. <i>Nutrition Research</i> , 2018, 49, 23-36.	1.3	44
17	Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles. <i>Journal of Controlled Release</i> , 2015, 220, 61-70.	4.8	34
18	Recent Advances in Nanoencapsulation of Phytochemicals to Combat Obesity and Its Comorbidities. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 8119-8131.	2.4	30

#	ARTICLE	IF	CITATIONS
19	Browning white adipose tissue using adipose stromal cell-targeted resveratrol-loaded nanoparticles for combating obesity. <i>Journal of Controlled Release</i> , 2021, 333, 339-351.	4.8	28
20	Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 419-427.	1.3	26
21	Anti-atherogenic effects of CD36-targeted epigallocatechin gallate-loaded nanoparticles. <i>Journal of Controlled Release</i> , 2019, 303, 263-273.	4.8	25
22	Plasma clearance and hepatic utilization of stearic, myristic and linoleic acids introduced via chylomicrons in rats. <i>Lipids</i> , 1993, 28, 697-703.	0.7	21
23	Associations between Tissue Visfatin/Nicotinamide, Phosphoribosyltransferase (Namt), Retinol Binding Protein-4, and Vaspin Concentrations and Insulin Resistance in Morbidly Obese Subjects. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	1.4	21
24	Lipid content in hepatic and gonadal adipose tissue parallel aortic cholesterol accumulation in mice fed diets with different omega-6 PUFA to EPA plus DHA ratios. <i>Clinical Nutrition</i> , 2014, 33, 260-266.	2.3	14
25	Indomethacin Enhances Brown Fat Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 467-475.	1.3	12
26	Preparation of flavanol-rich green tea extract by precipitation with AlCl ₃ . <i>Journal of the Science of Food and Agriculture</i> , 2001, 81, 1034-1038.	1.7	9
27	Aortic cholesterol accumulation correlates with systemic inflammation but not hepatic and gonadal adipose tissue inflammation in low-density lipoprotein receptor null mice. <i>Nutrition Research</i> , 2013, 33, 1072-1082.	1.3	8
28	Enhanced Aortic Macrophage Lipid Accumulation and Inflammatory Response in LDL Receptor Null Mice Fed an Atherogenic Diet. <i>Lipids</i> , 2010, 45, 701-711.	0.7	7
29	Nanoparticle-mediated in vitro delivery of E4orf1 to preadipocytes is a clinically relevant delivery system to improve glucose uptake. <i>International Journal of Obesity</i> , 2020, 44, 1607-1616.	1.6	7
30	Nanoparticles target intimal macrophages in atherosclerotic lesions. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 32, 102346.	1.7	7
31	Transdermal Delivery of Metformin Using Dissolving Microneedles and Iontophoresis Patches for Browning Subcutaneous Adipose Tissue. <i>Pharmaceutics</i> , 2022, 14, 879.	2.0	7
32	Blood leptin and C-reactive protein provide more sensitive assessment than blood lipids and other inflammatory biomarkers in overweight university students. <i>Nutrition Research</i> , 2011, 31, 586-593.	1.3	6
33	Comparing Effects of Native and Nanoencapsulated Epigallocatechin Gallate on Liver Fat Content in LDL Receptor Null Mice. <i>FASEB Journal</i> , 2015, 29, LB373.	0.2	1
34	Atherogenic Diet Promotes Atherosclerotic Lesion Formation by Enhancing Inflammatory Response in the LDL Receptor Null Mouse. <i>FASEB Journal</i> , 2009, 23, LB510.	0.2	0
35	Associations between blood lipid and inflammatory biomarkers and obesity in university students. <i>FASEB Journal</i> , 2011, 25, lb289.	0.2	0
36	Lower dietary n-6 polyunsaturated fatty acids: eicosapentaenoic acid plus docosahexaenoic acid ratio decreases the expression of inflammatory factors in livers and visceral adipose tissue in LDL receptor null mice. <i>FASEB Journal</i> , 2012, 26, 1026.17.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Nanoencapsulation increases ($\hat{\sim}$)â€epigallocatechin gallate stability and its cellular bioavailability in macrophages. FASEB Journal, 2012, 26, 646.5.	0.2	0
38	Epigallocatechin gallate (EGCG) â€loaded nanoparticles decrease cholesterol content in THPâ€1 derived macrophages. FASEB Journal, 2013, 27, 224.5.	0.2	0
39	Visfatin and vaspin protein concentrations in different tissues and insulin resistance. FASEB Journal, 2013, 27, 865.13.	0.2	0
40	Quercetin encapsulated nanocarriers: effects on breast cancer cell growth, apoptosis, and uptake in vitro and bioavailability in vivo. FASEB Journal, 2013, 27, 224.3.	0.2	0
41	All omega 3 fatty acids decrease macrophage prostaglandin E2 and inflammatory cytokine production (1034.16). FASEB Journal, 2014, 28, 1034.16.	0.2	0